Adherence to vascular protection drugs in diabetic patients in Quebec: A population-based analysis

Diabetes and Vascular Disease Research

Volumn 7, Issue 2, 2010, Pages 167-171

  Asghari, Shabnam ^a   Courteau, Josiane ^a   Drouin, Catherine ^a   Grégoire, Jean Pierre ^b   Carpentier, André C ^c   Pâquet, Mariane ^d   Vanasse, Alain ^a,c  

^a Centre Hospitalier Universitaire de Sherbrooke   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adherence; Diabetes; Medical record; Medication use; Vascular protection

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANADA; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT COMPLIANCE; POPULATION RESEARCH; VASCULAR DISEASE; DIABETIC ANGIOPATHY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; STATISTICS;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUEBEC; RETROSPECTIVE STUDIES;

EID: 77954465004     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109360593     Document Type: Article

References (12)

1. Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the prevention and Management of Diabetes in Canada. Can J Diabetes 2003; 27(Suppl 2):S37-S42, S58-S65.
2. Meitzer S, Leiter L, Daneman D, Gerstein H C, Lau D, Ludwig S, Yale JF, Zinman B, Lilhe D, Steering and Expert Committees. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med J 1998; 159(8 Suppl):Sl-S29.
3. Clinical Practice Guidelines Expert Committee, Fichett D, Kraw M. Vascular Protection in people with diabetes. Can J Diabetes 2008; 32(Suppl 1):S102- S106.
4. Vanasse A, Courteau J, Niyonsenga T. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. BMC CardiovascDisord 2006; 6: 21.
5. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200-209.
6. Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. J Manag Care Pharm 2006; 12: 649-655.
7. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-457.
8. Klarin I, Fastbom J, Wimo A. A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. Pharmacoepidemiol Drug Saf 2003; 12: 669-678.
9. Palin JA, Zumbo BD. Measurement of health care utilization in Canada: Agreement between surveys and administrative records. Catalogue no. 11-522-XIE, XIE, 2003.
10. Statistics Canada http://www.statcan.ca/english/research/92F0138MIE/ 2008002/discussion-en.htm (accessed 1 September 2008)
11. Loslier J, Vanasse A, Niyonsenga T, Courteau J, Orzanco G, Hemiari A. Myocardial infarction in Quebec rural and urban populations between 1995 and 1997. Can J Rural Med 2007; 12: 95-102.
12. Sirois C, Poirier P, Moisan J, Grégoire JP. The benefit of aspirin therapy in type 2 diabetes: what is the evidence? Int J Cardiol 2008; 129: 172-179.